Robert Nagele, PhD, received his PhD from Rutgers University. He is currently a professor of medicine at the New Jersey Institute for Successful Aging at the University of Medicine and Dentistry of New Jersey. He lists 100 published research articles which, for the past decade, have focused on mechanisms of Alzheimer’s disease pathogenesis.  More recently, his studies have broadened to include other neurodegenerative diseases, including Parkinson’s disease, with emphasis on the role of blood-borne autoantibodies in the initiation and progression of these diseases. Most recently, he discovered that autoantibodies are both ubiquitous and abundant in human sera, a finding that led to the identification of disease-specific autoantibodies that can be used as diagnostic indicators for Alzheimer’s and Parkinson’s diseases. This work has prompted the establishment of two companies focused on the development of disease diagnostics: Durin Technologies, Inc. and Beren Technologies, Inc., where Dr. Nagele serves as founder and chief scientific officer.